LA Financiere DE L Echiquier Buys Shares of 23,473 Lantheus Holdings, Inc. (NASDAQ:LNTH)

LA Financiere DE L Echiquier acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 23,473 shares of the medical equipment provider's stock, valued at approximately $1,455,000.

A number of other institutional investors have also recently bought and sold shares of the business. Fairfield Bush & CO. acquired a new stake in shares of Lantheus during the 1st quarter worth $177,000. Raymond James & Associates acquired a new stake in shares of Lantheus in the first quarter valued at about $856,000. Bank of New York Mellon Corp raised its position in shares of Lantheus by 2.7% during the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider's stock worth $34,791,000 after acquiring an additional 16,422 shares during the last quarter. American Century Companies Inc. raised its holdings in Lantheus by 14.4% during the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider's stock worth $1,064,000 after purchasing an additional 2,427 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new position in shares of Lantheus in the 1st quarter worth approximately $354,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business's stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold 94,545 shares of company stock valued at $6,168,153 in the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Lantheus Price Performance

LNTH stock traded down $1.09 during trading on Monday, hitting $59.74. 668,917 shares of the company's stock traded hands, compared to its average volume of 1,104,587. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The stock has a market capitalization of $4.10 billion, a price-to-earnings ratio of 12.88 and a beta of 0.54. The business has a fifty day simple moving average of $59.52 and a 200 day simple moving average of $63.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts' consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to analysts' expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. As a group, research analysts expect that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent analyst reports. William Blair downgraded Lantheus from an "outperform" rating to a "market perform" rating in a research note on Monday, December 18th. JMP Securities reiterated a "market outperform" rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Truist Financial reiterated a "buy" rating and issued a $82.00 target price (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. TheStreet lowered shares of Lantheus from a "b-" rating to a "c" rating in a research note on Monday, December 18th. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Saturday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $104.14.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.